McGiffin David C, Brown Robert, Kirklin James K, Naftel David C, Bourge Robert C, Pritzker Marc R, Kasper Edward K, Stevens Tracy, Clemson Barry S, Smith Andrew L, Hill James A, Rodeheffer Richard J
University of Alabama at Birmingham, Birmingham, AL 35294, USA.
J Heart Lung Transplant. 2005 Mar;24(3):259-69. doi: 10.1016/j.healun.2004.01.011.
Cardiac transplant recipients have been regarded as not medically fit to fly an airplane. Recently, the Federal Aviation Administration decided to re-examine this policy and, in response, this study was undertaken to determine the risk of death from any cause and sudden-onset death in heart transplant recipients during the 12 months after an annual evaluation.
Of 6,510 patients undergoing primary orthotopic cardiac transplantation enrolled in the Cardiac Transplant Research Database (CTRD), 4,978 patients survived for at least 1 year and formed the basis of this study. Risk factors for death from any causes and sudden-onset death (a composite of causes of death that could conceivably result in a pilot's incapacitation) were determined during the 12-month period after an anniversary evaluation. Patients were re-entered into the analysis at each evaluation, resulting in a total of 23,575 anniversary evaluations.
The presence of coronary allograft vasculopathy (CAV), left ventricular systolic dysfunction, history of rejection, malignancy, infection and pre-transplant insulin-dependent diabetes were associated with an increased risk of death from any cause and sudden-onset death during the 12-month period after an evaluation. Based on the absence of these risk factors, a group of heart transplant recipients could be defined with a 12-month risk of death from any cause of 1.0% and of sudden-onset death of 0.3% (which is identical to the mortality rate of a matched population from the U.S. life-table).
Using these identified risk factors, a group of heart transplant recipients can be defined that are potentially medically certifiable to fly without compromising aviation safety.
心脏移植受者一直被认为在医学上不适合驾驶飞机。最近,美国联邦航空管理局决定重新审视这一政策,为此开展了本研究,以确定心脏移植受者在年度评估后的12个月内任何原因导致的死亡风险和猝死风险。
在心脏移植研究数据库(CTRD)登记的6510例接受原位心脏移植的患者中,4978例存活至少1年,构成了本研究的基础。在周年评估后的12个月内,确定任何原因导致的死亡和猝死(可能导致飞行员丧失能力的死因组合)的危险因素。每次评估时患者重新纳入分析,共进行了23575次周年评估。
冠状动脉移植血管病变(CAV)、左心室收缩功能障碍、排斥反应史、恶性肿瘤、感染和移植前胰岛素依赖型糖尿病与评估后12个月内任何原因导致的死亡和猝死风险增加相关。基于这些危险因素的不存在,可以定义一组心脏移植受者,其12个月内任何原因导致的死亡风险为1.0%,猝死风险为0.3%(与美国生命表中匹配人群的死亡率相同)。
利用这些确定的危险因素,可以定义一组心脏移植受者,他们在不影响航空安全的情况下可能在医学上获得飞行认证。